Abstract: The present disclosure relates to compound of structural Formula I and a method for preparing said compounds. The disclosure further relates to a method of employing the Formula I compounds for modulation of Janus kinase-Signal Transducer and Activator of Transcription (JAK-STAT) pathway in cancer cells, and the corresponding use of compound of Formula I as anti-cancer agents.

Abstract: The present disclosure relates to compound of structural Formula I and a method for preparing said compounds. The disclosure further relates to a method of employing the Formula I compounds for modulation of Janus kinase-Signal Transducer and Activator of Transcription (JAK-STAT) pathway in cancer cells, and the corresponding use of compound of Formula I as anti-cancer agents.

Abstract: Disclosed are methods of diagnosing liver cancer in a subject as well as methods of assessing the risk of a subject having chronic hepatitis and liver cirrhosis of developing liver cancer. Also disclosed are kits for the diagnosis of liver cancer.

Abstract: The present invention provides a microfluidic device comprising a plurality of wells, each of which may be substantially filled with a liquid without either the need for expensive individual sample loading or the requirement to isolate individual wells to prevent cross contamination and sample evaporation. A base member (2) comprises a plurality of wells (4) in the form of an array, an inlet channel (6) and three outlets (8).

Abstract: The present invention relates to genetic sequences exhibiting differential expression patterns in cancer tissue relative to normal tissue. The identification of such sequences permits their use as molecular markers for cancer, as early indicators of cancer progression and/or as predictive markers for a propensity or likelihood of a cancer to develop. The present invention relates particularly to genetic sequences exhibiting expression patterns up-regulated in cervical cells or associated with pre-, early- or late-onset cervical cancer relative to normal cervical cells, such sequences serving as biomarkers. The biomarkers of the present invention provide targets for the development of therapeutic protocols for the treatment or prophylaxis of cervical or related cancer. Such therapeutic protocols are directed to inhibiting expression of the marker or inhibiting the expression product of the marker.

Abstract: Compositions have been obtained by extracting rhizomes of Fagopyrum dibotrys with alcohol and concentrating the extract to a powder or syrup, optionally followed by fractionation. The extract is demonstrated to be a potent anti-cancer agent. Its activity at the gene level was analysed.

Abstract: The present invention relates generally to genetic sequences exhibiting differential expression patterns in cancer tissue relative to normal tissue. The identification of differentially expressed genetic sequences permits their use as molecular markers for cancer, as early indicators of cancer progression and/or as predictive markers for a propensity or likelihood of a cancer to develop. The present invention relates particularly to genetic sequences exhibiting expression patterns up-regulated in cervical cells or associated with pre-, early- or late-onset cervical cancer relative to normal cervical cells. The genetic sequences of the present invention provide markers for early- or late-onset cervical cancer and/or a cancer related to cervical cancer. The markers of the present invention further provide potential targets for the development of therapeutic protocols for the treatment or prophylaxis of cervical or related cancer.

Abstract: The present invention relates generally to genetic sequences exhibiting differential expression patterns in cancer tissue relative to normal tissue. The identification of differentially expressed genetic sequences permits their use as molecular markers for cancer, as early indicators of cancer progression and/or as predictive markers for a propensity or likelihood of a cancer to develop. The present invention relates particularly to genetic sequences exhibiting expression patterns up-regulated in cervical cells or associated with pre-, early- or late-onset cervical cancer relative to normal cervical cells. The genetic sequences of the present invention provide markers for early- or late-onset cervical cancer and/or a cancer related to cervical cancer. The markers of the present invention further provide potential targets for the development of therapeutic protocols for the treatment or prophylaxis of cervical or related cancer.